The Effect of Resveratrol Supplementation on Cardio‐Metabolic Risk Factors in Patients with Type 2 Diabetes: A Randomized, Double‐Blind Controlled Trial

Abdollahi, Shima; Salehi‐Abargouei, Amin; Toupchian, Omid; Sheikhha, Mohammad Hasan; Fallahzadeh, Hossein; Rahmanian, Masoud; Tabatabaie, Mahtab; Mozaffari‐Khosravi, Hassan

doi:10.1002/ptr.6487

Cited by 43 publications

(39 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A second meta-analysis of clinical studies with resveratrol in T2D patients (nine randomized controlled trials with 283 subjects) reported that resveratrol could significantly reduce levels of FBS with concomitant beneficial effects on HOMA-IR scores and levels of insulin [42]. Very recently, a randomized clinical trial involving 71 overweight patients with T2D reported that eight-week resveratrol supplementation was able to significantly improve cardiac and metabolic parameters [46]. Furthermore, another recent randomized, double-blind, placebo-controlled trial with 56 patients having T2D and coronary artery disease reported that resveratrol reduced hyperglycemia and levels of MDA and improved the levels of HDL-cholesterol, the total-/HDL-cholesterol ratio, and TAC [47].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Resveratrol in Type 1 Diabetes Patients: A Two-Month Preliminary Exploratory Trial

et al. 2020

View full text Add to dashboard Cite

Resveratrol has been reported to be beneficial against diabetes complications. The objective of this study was to evaluate the efficacy of resveratrol in decreasing hyperglycemia in patients with type 1 diabetes (T1D) by a preliminary investigation designed as an exploratory clinical trial. Thirteen patients with T1D from both the sexes participated in this trial. All patients received resveratrol in 500 mg capsules, twice daily for 60 days. Bodyweight, fasting blood sugar (FBS), hemoglobin A1c (HbA1c), insulin, homeostasis model of assessment for insulin resistance (HOMA-IR), homeostasis model of assessment for β-cell function (HOMA-β), and markers of liver and kidney damage, inflammation, and oxidative stress were measured before the intervention, at 30 days and at 60 days. Resveratrol supplementation for 60 days significantly decreased FBS and HbA1c in comparison with the baseline values. Resveratrol treatment also resulted in a decrease in the level of a marker for oxidative stress, malondialdehyde, and an increase in total antioxidant capacity in T1D patients. Insulin, HOMA-IR, HOMA-β, and markers of liver and kidney function and inflammation were not significantly affected by resveratrol treatment. Overall, the results showed that 60 days of resveratrol supplementation exerted strong antidiabetic and antioxidant effects in patients with T1D.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Resveratrol in Type 1 Diabetes Patients: A Two-Month Preliminary Exploratory Trial

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It also resulted in a decrease in the level of MDA and an increase in TAC in patients with T1D [ 39 ]. In patients with T2D, almost the same effect was happened [ 40 , 41 ]. However, an invalid prescription has been reported in T2D patients, which is due to the complexity of human genetics and other factors [ 42 ].…”

Section: Non-flavonoidsmentioning

confidence: 79%

Natural Polyphenols in Metabolic Syndrome: Protective Mechanisms and Clinical Applications

Zhang

et al. 2021

IJMS

View full text Add to dashboard Cite

Metabolic syndrome (MetS) is a chronic disease, including abdominal obesity, dyslipidemia, hyperglycemia, and hypertension. It should be noted that the occurrence of MetS is closely related to oxidative stress-induced mitochondrial dysfunction, ectopic fat accumulation, and the impairment of the antioxidant system, which in turn further aggravates the intracellular oxidative imbalance and inflammatory response. As enriched anti-inflammatory and antioxidant components in plants, natural polyphenols exhibit beneficial effects, including improving liver fat accumulation and dyslipidemia, reducing blood pressure. Hence, they are expected to be useful in the prevention and management of MetS. At present, epidemiological studies indicate a negative correlation between polyphenol intake and MetS incidence. In this review, we summarized and discussed the most promising natural polyphenols (including flavonoid and non-flavonoid drugs) in the precaution and treatment of MetS, including their anti-inflammatory and antioxidant properties, as well as their regulatory functions involved in glycolipid homeostasis.

show abstract

“…Both RSV supplementation and ER did not change serum hs-CRP, glucose, and HOMA-IR significantly at the end of the study. There is evidence that 1000 mg/day of RSV may reduce glycemia [ 44 ]. However, it seems that beneficial effects of RSV on glucose metabolism occur when administration dose is higher than 500 mg and in a period higher than 10 weeks, explaining why in the present 30-day intervention study there were no significant alterations observed [ 45 ].…”

Section: Discussionmentioning

confidence: 99%

Comparison of Resveratrol Supplementation and Energy Restriction Effects on Sympathetic Nervous System Activity and Vascular Reactivity: A Randomized Clinical Trial

et al. 2021

View full text Add to dashboard Cite

Background: Chronic sympathetic nervous system activation is associated with endothelial dysfunction and cardiometabolic disease, which may be modulated by resveratrol (RSV) and energy restriction (ER). This study aimed to examine the effects of RSV and ER on plasma noradrenaline (NA), flow-mediated vasodilation (ed-FMD), and endothelium-independent nitrate-mediated vasodilation (ei-NMD). Methods: The study included 48 healthy adults randomized to 30-days intervention of RSV or ER. Results: Waist circumference, total cholesterol, HDL-c, LDL-c, apoA-I, and plasma NA decreased in the ER group, whilst RSV increased apoB and total cholesterol, without changing plasma NA. No effects on vascular reactivity were observed in both groups. Plasma NA change was positively correlated with total cholesterol (r = 0.443; p = 0.002), triglycerides (r = 0.438; p = 0.002), apoA-I (r = 0.467; p = 0.001), apoB (r = 0.318; p = 0.032) changes, and ei-NMD (OR = 1.294; 95%CI: 1.021–1.640). Conclusions: RSV does not improve cardiometabolic risk factors, sympathetic activity, and endothelial function. ER decreases plasma NA and waist circumference as well as improves blood lipids, but does not modify endothelial function. Finally, plasma NA was associated with ei-NMD, which could be attributed to a higher response to nitrate in patients with greater resting sympathetic vasoconstriction.

show abstract

The Effect of Resveratrol Supplementation on Cardio‐Metabolic Risk Factors in Patients with Type 2 Diabetes: A Randomized, Double‐Blind Controlled Trial

Cited by 43 publications

References 69 publications

Efficacy and Safety of Resveratrol in Type 1 Diabetes Patients: A Two-Month Preliminary Exploratory Trial

Efficacy and Safety of Resveratrol in Type 1 Diabetes Patients: A Two-Month Preliminary Exploratory Trial

Natural Polyphenols in Metabolic Syndrome: Protective Mechanisms and Clinical Applications

Comparison of Resveratrol Supplementation and Energy Restriction Effects on Sympathetic Nervous System Activity and Vascular Reactivity: A Randomized Clinical Trial

Contact Info

Product

Resources

About